|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Illumina, Inc. (NASDAQ: ILMN), a developer of tools for the large-scale analysis of genetic variation and function. |
|---|---|
| Transferring Party | Solexa, Inc. (NASDAQ: SLXA), a U.K. based developer of genetic analysis systems for use in whole genome sequencing, targeted resequencing, digital gene expression and microRNA analysis. |
| Sector | Diagnostics |
| Date | January 26, 2007 |
| Analysis Creates the only company with genome-scale technology for genotyping, gene expression and sequencing, the three cornerstones of modern genetic analysis. Leverages Illumina's global sales and support infrastructure. Stock-for-stock merger valued at - $600m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |